Kymera Therapeutics Inc (NASDAQ: KYMR) kicked off on Tuesday, down -4.36% from the previous trading day, before settling in for the closing price of $22.01. Over the past 52 weeks, KYMR has traded in a range of $19.75-$53.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 233.20%. While this was happening, its average annual earnings per share was recorded -21.97%. With a float of $53.93 million, this company’s outstanding shares have now reached $64.89 million.
Let’s determine the extent of company efficiency that accounts for 188 employees. In terms of profitability, gross margin is 88.53%, operating margin of -545.36%, and the pretax margin is -475.57%.
Kymera Therapeutics Inc (KYMR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 16.95%, while institutional ownership is 95.07%. The most recent insider transaction that took place on Mar 03 ’25, was worth 68,239. In this transaction Chief Legal Officer of this company sold 2,241 shares at a rate of $30.45, taking the stock ownership to the 80,085 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Operating Officer sold 1,383 for $30.45, making the entire transaction worth $42,113. This insider now owns 67,800 shares in total.
Kymera Therapeutics Inc (KYMR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.17% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Take a look at Kymera Therapeutics Inc’s (KYMR) current performance indicators. Last quarter, stock had a quick ratio of 7.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -4.11 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Looking closely at Kymera Therapeutics Inc (NASDAQ: KYMR), its last 5-days average volume was 0.99 million, which is a jump from its year-to-date volume of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 11.88%. Additionally, its Average True Range was 2.27.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 3.97%, which indicates a significant decrease from 8.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.32% in the past 14 days, which was lower than the 64.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.32, while its 200-day Moving Average is $41.14. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $23.14. Second resistance stands at $25.22. The third major resistance level sits at $26.66. If the price goes on to break the first support level at $19.61, it is likely to go to the next support level at $18.16. Should the price break the second support level, the third support level stands at $16.08.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
The company with the Market Capitalisation of 1.37 billion has total of 64,944K Shares Outstanding. Its annual sales at the moment are 47,070 K in contrast with the sum of -223,860 K annual income. Company’s last quarter sales were recorded 7,390 K and last quarter income was -70,750 K.
